These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 12535234)

  • 1. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
    Weinstein MC; O'Brien B; Hornberger J; Jackson J; Johannesson M; McCabe C; Luce BR;
    Value Health; 2003; 6(1):9-17. PubMed ID: 12535234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable.
    Garrison LP
    Value Health; 2003; 6(1):6-8. PubMed ID: 12535233
    [No Abstract]   [Full Text] [Related]  

  • 7. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
    Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
    Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.
    Johnson ML; Crown W; Martin BC; Dormuth CR; Siebert U
    Value Health; 2009; 12(8):1062-73. PubMed ID: 19793071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluations of Multicomponent Disease Management Programs with Markov Models: A Systematic Review.
    Kirsch F
    Value Health; 2016 Dec; 19(8):1039-1054. PubMed ID: 27987631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
    Berger ML; Mamdani M; Atkins D; Johnson ML
    Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making.
    Drummond M; Brown R; Fendrick AM; Fullerton P; Neumann P; Taylor R; Barbieri M;
    Value Health; 2003; 6(4):407-16. PubMed ID: 12859580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.